Updates, milestones, and links shared by SingleCell Biotechnology.
Awarded CPRIT Grant for $2.5M to further the optimization of the plaform assays and demonstrate drug development in finding new biomarkers to combat difficult cancers.
Platform successfully tested with primary tumor cells direct from operating room to show that it has the ability to be used as a diagnostic device.
4 well device version of platform devices made ready for production, past the prototype stage.
Demonstrated that the platform can be used to identify re-purposed drugs that can be used to enhance or provide improved treatment outcomes.
Used platform to demonstrate how current drugs and radiation have little to no effect on migrating and dormant cancer cells. Further showing that current treatments targeting rapidly dividing cells leave this lethal population of non-dividing cells behind.
Platform successfully demonstrated on prototype devices to demonstrate single cell dormancy, migration, and clonogenic assays with both Glioblastoma (brain) cancer and breast cancer patient derived cell lines.